全球药品市场前景及投资研究报告-培训课件外文版2024.5

INDUSTRIES

&

MARKETSPharmaceuticalmarketworldwideCHAPTER

01OverviewRevenueoftheworldwidepharmaceuticalmarketfrom2001to2022(inbillionU.S.dollars)Pharmaceuticalmarket:worldwiderevenue2001-20221,6001,4001,2001,0001,4821,4501,3121,2781,204.81,135.11,115.71,073.11,063.6993.8963.2

964.4888.2830.6799800726.4648.7601.2559.96004002000498427.6390.22001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

20224Description:Theglobalpharmaceuticalmarkethasexperiencedsignificantgrowthinrecentyears.For2022,thetotalglobalpharmaceuticalmarketwasestimatedat1.48trillionU.S.dollars.Thisisaonlyaslightincreasefrom2021whenthemarketwasvaluedat1.42trillionU.S.dollars.Thepharmaceuticalmarketplaysakeyroleinhowpeoplegetmedicationsandwhatpeoplepayformedication.However,somemarketsarebetterforpharmaceuticalcompaniesthanothers.

ReadmoreNote(s):WorldwideSource(s):IQVIAGlobalpharmaceuticalsalesfrom2020to2022,byregion(inbillionU.S.dollars)Worldpharmaceuticalsales2020-2022byregionWorldtotalUnitedStatesEmergingmarketsEuropeEstablishedROW*2020202120225Description:Thisstatisticdescribestheglobalpharmaceuticalsalesinfrom2020toQ32022,sortedbyregionalsubmarkets.AsofQ32022,totalpharmaceuticalsalesintheUnitedStateswasestimatedtoreacharound605billionU.S.dollarsinthatyear.

ReadmoreNote(s):Worldwide;2020toQ32022Source(s):AstraZeneca;IQVIADistributionofthetotalglobalpharmaceuticalmarketsalesfrom2014to2022,bysubmarketWorldpharmaceuticalmarketdistributionbysubmarket2014-2022UnitedStates46%EuropeOtherestablishedmarkets48%Emergingmarkets48%60%50%40%30%20%10%0%50%47%47%46%45%45%24%24%22%22%22%21%13%21%21%21%21%21%20%20%20%20%19%19%18%13%12%11%11%11%11%10%9%2014201520162017201820192020202120226Description:Thisstatisticshowsthedistributionofthetotalglobalpharmaceuticalmarketsalesfrom2014to3rdquarterof2022,bysubmarket.In2022,theU.S.pharmaceuticalmarketgeneratedsome50percentoftotalglobalmarketsales.

ReadmoreNote(s):Worldwide;2014toQ32022Source(s):AstraZeneca;IQVIARevenuesofleading10nationalpharmaceuticalmarketsworldwidein2022(inbillionU.S.dollars)Revenuesoftop10globalpharmaceuticalmarkets2022RevenueinbillionU.S.dollars3000100200400500600700UnitedStatesChina*631.5112.6Japan67.259.5GermanyFrance41.836.1ItalyUnitedKingdomCanada33.429.428.528.2SpainBrazil**7Description:In2022,therevenueoftheChinesepharmaceuticalmarkettotaledapproximately113billionU.S.dollars.Thisstatisticshowstherevenuesofthetop10nationalpharmaceuticalmarketsworldwidein2022.TheUnitedStatesremainsbyfarthelargestmarketforpharmaceuticalproducts,generatingmorerevenuethanallothercountriesfromthetop10listcombined.ReadmoreNote(s):WorldwideSource(s):IQVIALeadingpharmaceuticalproductsbysalesworldwidein2022(inbillionU.S.dollars)Toppharmaceuticalproductsbysalesworldwide2022SalesinbillionU.S.dollars15

2005102530354045Comirnaty(BioNTech/Pfizer)Spikevax(Moderna)Humira(AbbVie)40.821.821.6Keytruda(Merck&Co.)Paxlovid(Pfizer)2119Eliquis(BMS)11.8Biktarvy(Gilead)10.410.3Eylea(Bayer/Regeneron)Stelara(JanssenBiotech)Revlimid(BMS)10.1108Description:Unlikeintheyearsbefore2021,U.S.companyAbbVie`sHumiradidnotmaintainitsplaceastheglobaltoprankeddrugbasedonrevenue.During2022,Covid-19vaccineComirnatywastopperformingpharmaceuticalproduct,generatingsome40.8billionU.S.dollarsinrevenue.Humiracameinasthirdrankeddrugin2022,withrevenuestotaling21.6billiondollars.ReadmoreNote(s):WorldwideSource(s):Evaluate(EvaluatePharma);NatureCHAPTER

02SegmentsProjectedtoptherapyareasworldwidein2027,byspending(inbillionU.S.dollars)Toptherapyclassesbyspendingglobalmarket2027forecastSpendinginbillionU.S.dollars150

200050100250300350400OncologyImmunology377177168DiabetesCardiovascular126Respiratory92CentralnervoussystemInfectiousdiseasesGenitourinary/sexualhealthGastrointestinalproductsMentalHealth817458524810Description:Thisstatisticshowsthetoptherapyareasworldwidebyprojectedspendingin2027,inbillionU.S.dollars.By2027,spendingononcologyisprojectedtobeatsome377billionU.S.dollars.Immunologyisprojectedtobesecondwitharound177billiondollarsofspending.ReadmoreNote(s):Worldwide;asofNovember2022Source(s):IQVIAGlobalpharmaceuticalrevenuedistributedbytechnologyfrom2012to2026(inbillionU.S.dollars)Globalpharmaceuticalrevenuebytechnology2012-2026BiotechnologyConventionalOtherunclassifiedsales1,6001,4001,2001,0008002466812286442126062015661915361831804761754691764611774471754461814471714401704431774356005054005054612004163783443122662842421621791972151741490201220132014201520162017201820192020*20212022202320242025202611Description:Thisstatisticdepictstheglobalpharmaceuticalrevenue-includingprescriptionandover-the-counterdrugs-from2012to2026,categorizedbytechnology.In2019,biotechnologyaccountedfor266billionU.S.dollarsindrugrevenuewhileconventionaldrugsaccumulated469billionU.S.dollars,andunclassifiedtechnologyaccountedfor175billionU.S.dollarsofrevenue.Biotechnologyallowsfortheutilizationoflivingsystemsandorganismstocreatepharmaceuticalproducts.The[...]

ReadmoreNote(s):WorldwideSource(s):EvaluatePrescriptiondrugssalesworldwideexcludinggenericsandorphandrugsfrom2012to2026(inbillionU.S.dollars)WorldwideRxdrugsalesexcludinggenericsandorphandrugs2012-20261,2001,0001,04096790184681779480068968165962461361459859859860040020002012201320142015201620172018201920202021*2022202320242025202612Description:Thisstatisticshowsthesalesofprescriptiondrugsworldwideexcludinggenericsandorphandrugs,from2012to2026,inbillionU.S.dollars.In2012,salesforprescriptiondrugsexcludinggenericsandorphanstoodatsome598billionU.S.dollarswhichisestimatedtoincreaseuptooveronetrillionU.S.dollarsin2026.ReadmoreNote(s):Worldwide;asofMay2021Source(s):EvaluateGlobalprescriptionorphandrugsalesfrom2018to2028(inbillionU.S.dollars)Projectionofglobalrevenuefororphanprescriptiondrugs2018-2028350300250200300273244220195173156148150100501301131029102016201820192020202120222023*2024202520262027202813Description:Thisstatisticshowstheworldwiderevenuegeneratedthroughprescriptionorphandrugsfrom2018to2028.In2022,orphandrugsrevenuestotaled156billionU.S.dollars.Orphandrugsareusedtotargetrarediseasesordisorders,whichintheUnitedStatesisdefinedaslessthan200,000patients.ThedevelopmentoforphandrugsarecurrentlyincentivizedintheUnitedStatesthroughtheOrphanDrugActof1983.ReadmoreNote(s):Worldwide;2018to2023Source(s):EvaluateWorldwidegenericprescriptiondrugsalesfrom2012to2026(inbillionU.S.dollars)Worldwidegenericprescriptiondrugsales2012-20261209996100928985828281787680604020074747470672012201320142015201620172018201920202021*2022202320242025202614Description:Thisstatisticdepictsthetotalgenericprescriptiondrugsalesworldwidefrom2012to2026.In2020,theindustrygenerated74billionU.S.dollarsingenericprescriptiondrugsalesworldwide.Until2026,globalprescribedgenericssalesareexpectedtoreachnearly100billionU.S.dollars.Genericsaremuchcheapercopiesoforiginallybrandeddrugswhichlosttheirpatentprotection.Throughtheuseofgenericsinsteadofbranded/patentprotecteddrugs,savingsofmanybillionsofdollars[...]

ReadmoreNote(s):Worldwide;2012to2020Source(s):EvaluateRevenueoftheOTCpharmaceuticalsmarketworldwidefrom2017to2028(inbillionU.S.dollars)RevenueoftheOTCpharmaceuticalsindustryworldwide2017-2028300250200243.6233.05222.5212.19202.39193.11184.29176.61168.15164.06157.96152.0515010050020172018201920202021202220232024202520262027202815Description:TheglobalrevenueintheOTCpharmaceuticalsmarketwasforecasttocontinuouslyincreasebetween2023and2028byintotal50.5billionU.S.dollars(+26.15percent).Aftertheeleventhconsecutiveincreasingyear,theindicatorisestimatedtoreach243.6billionU.S.dollarsandthereforeanewpeakin2028.Notably,therevenueoftheOTCpharmaceuticalsmarketwascontinuouslyincreasingoverthepastyears.

ReadmoreNote(s):Worldwide;2017to2028Source(s):Globaloncologyspendingfrom2011to2024(inbillionU.S.dollars)Globaloncologyspending2011-20243002532502181932001501005017315513811710290796961020132014201520162017201820192020202120222023*2024*16/statistics/696208/oncology-costs-worldwideThisstatisticshowstotaloncologyspendingworldwide,includingspendingforsupportivecare,from2010to2024.In2022,globaloncologyspendingtotaled193billionU.S.dollars.Incomparison,costsstoodat90billiondollarssixyearsearlier.

ReadmoreNote(s):WorldwideSource(s):IQVIACHAPTER

03CompaniesLeading50globalpharmaceuticalcompaniesbyprescriptionsalesandR&Dspendingin2022(inbillionU.S.dollars)Top50pharmaceuticalcompanies-RxsalesandR&Dspending2022Sales/spendinginbillionU.S.dollarsResearchanddevelopmentspending20

30

40Prescriptionsales50

6001070809010012.38Pfizer(U.S.)AbbVie(U.S.)91.36.4456.1814.14Johnson&Johnson(U.S.)Novartis(Switzerland)Merck&Co.(U.S.)Roche(Switzerland)BristolMyersSquibb(U.S.)AstraZeneca(UK)Sanofi(France)50.179.0950.0849.6311.8414.7847.9145.4210.029.57.166.344.74.974340.3538.25GSK(UK)Takeda(Japan)GileadSciences(U.S.)29.6926.6218Description:Thetop50pharmaceuticalcompaniesbyprescriptionsalesin2022-andtheirresearchanddevelopment(R&D)spending-includedbignamessuchasPfizer,Novartis,andAbbVie.Duringthatyear,Pfizer'sRxsaleswereapproximately91billiondollars.Thus,theAmericanpharmagiantwasboththelargestpharmaceuticalcompanybasedonpurepharmarevenueworldwideandthethirdrankedpharmaceuticalcompanybasedonR&Dspending.Pfizerspent12.38billionU.S.dollarson[...]

ReadmoreNote(s):WorldwideSource(s):Evaluate(EvaluatePharma);PharmaceuticalExecutive;Varioussources(companydata)Leading10biotechandpharmaceuticalcompaniesworldwidebasedonmarketcapitalizationasof2023(inbillionU.S.dollars)Top10biotechandpharmaceuticalcompaniesbasedonmarketcap2023MarketcapinbillionU.S.dollars050100150200250300350400450500498.6550EliLillyandCo.,U.S.Johnson&Johnson,U.S.NovoNordisk,DenmarkAbbVieInc.,U.S.374.1302260.2258.2Merck&CoInc.,U.S.NovartisAG,SwitzerlandRocheHoldingAG,SwitzerlandAstraZenecaPLC,UKPfizerInc.,U.S.228.1219.2204.4191.4AmgenInc.,U.S.139.619Description:AsofOctober2023,EliLillyhadamarketcapofnearlyhalfatrillionU.S.dollarsandthuswasthenewleaderamongbigpharmacompaniesbasedonmarketcapitalization.EliLilly'sriseisbasedtoalargepartonitsstrongpipeline.Thisstatisticdepictsthetop10biotechandpharmaceuticalcompaniesworldwidebasedonmarketcapitalizationasof2023.ReadmoreNote(s):Worldwide;asofOctober2023Source(s):FinancialTimes;LondonStockExchangeLeadingpharmaceuticalcompaniesworldwidebasedonmarketsharein2022Globalpharmamarketsharebytopcompanies2022Marketshare4%0%1%2%3%5%6%7%8%9%9%10%PfizerRoche6%Johnson&JohnsonAbbVie5%5%5%5%Merck&Co.NovartisAstraZenecaSanofi4%4%4%BristolMyersSquibbGileadSciencesEliLilly3.3%3%20Description:Pfizerheldninepercentoftheworld'spharmaceuticaldrugmarketin2022.TheglobalmarketforprescribedmedicinesisexpectedtobeledbyU.S.companies,accompaniedbySwisspharmagiantsRocheandNovartis.

ReadmoreNote(s):Worldwide;2022Source(s):HealthMarketInsightsPfizer'stotalrevenuefrom2006to2022(inmillionU.S.dollars)Pfizer'stotalrevenue2006-2022120,000100,000100,33081,28880,00065,165

65,25960,00040,00020,000054,65753,64752,824

52,54651,58451,75049,07849,605

48,85148,37147,733

47,52941,6512020*200620072008200920102011201220132014201520162017201820192021202221Description:Pfizerisaglobalpharmaceuticalcompanyandamongthetoppharmaceuticalcompaniesintheworld.PfizerisheadquarteredinNewYorkCity.In2022,thecompany'stotalrevenueexceeded100billionU.S.dollarsforthefirsttime,arecordamongglobaldrugmanufacturers.Thiswasanothersignificantincreasecomparedtotheyearsbefore2020and,ofcourse,aconsequenceoftherecord-breakingsalesofCOVID-19vaccineComirnaty.

ReadmoreNote(s):WorldwideSource(s):PfizerTotalsalesoftheRocheGroupfrom2006to2022(inmillionSwissfrancs)RocheGroup'stotalsales2006-202270,00063,28162,80161,46658,32360,00050,00040,00030,00020,00010,000056,84653,29950,57649,05148,14547,47347,46246,78046,13345,61745,49942,53142,0412006200720082009201020112012201320142015201620172018201920202021202222Description:In2022,theRocheGroup,aSwisspharmaceuticalcompany,generatedover63billionSwissfrancsintermsoftotalsales.ThisstatisticshowstheannualsalesdevelopmentofRochesince2006.

ReadmoreNote(s):WorldwideSource(s):RocheJohnson&Johnson'stotalsalesfrom2005to2022(inmillionU.S.dollars)Johnson&Johnson'stotalsales2005-2022100,00090,00080,00070,00060,00050,00040,00030,00020,00010,000094,94393,77582,58481,581

82,05976,45074,33171,89071,31270,07467,22465,03063,74761,897

61,58761,09553,32450,51420052006200720082009201020112012201320142015201620172018201920202021202223Description:In2022,Johnson&Johnson'sgeneratedapproximately95billionU.S.dollarsinsales.ThisstatisticshowstheglobaltotalsalesofJohnson&Johnsonfrom2005to2022.Johnson&Johnsonisamultinationalcompany,specializedinpharmaceuticals,medicaldevices,andconsumergoods.ThecompanyisheadquarteredinNewBrunswick,NewJersey.ReadmoreNote(s):WorldwideSource(s):Johnson&JohnsonAbbVie'srevenuefrom2010and2022(inmillionU.S.dollars)AbbVie'srevenue2010-202270,00060,00050,00058,05456,19745,80440,00030,00020,00010,000033,26632,75328,21625,63822,859201519,960201418,790201318,380201217,444201115,6382010201620172018201920202021202224Description:ThisstatisticillustratestherevenueofAbbViefrom2010to2022.In2022,AbbViegarneredrevenuetotalingsome58billionU.S.dollars.AbbotLaboratorieswasaU.S.-basedglobalpharmaceuticalandhealthcareproductscompany,headquarteredinChicago,Illinois.InJanuary2013,Abbottwasseparatedintotwocompanies:AbbottLaboratoriesandAbbVie.AbbottLaboratoriesisnowspecializedonmedicalproducts,whileAbbVieisresponsibleforresearch-basedpharmaceuticals.OnMay[...]

ReadmoreNote(s):Worldwide;2010to2022Source(s):AbbVieLeadingpharmaceuticalcompaniesworldwidebasedonprojectedsalesincreaseduring2023(inbillionU.S.dollars)Projectedtoppharmaceuticalcompaniesbasedonnewsales2023SalesincreaseinbillionU.S.dollars0.00.51.01.52.02.53.03.53.44.0NovoNordiskAstraZenecaEliLilly2.51.9Bristol-MyersSquibbJohnson&JohnsonAmgen1.61.41.3CSL1.11.1NovartisGrifols0.90.9DaiichiSankyo25Description:Thisstatisticdepictsthetoppharmaceuticalcompaniesbasedonprojectedsalesincreaseduring2023comparedtothepreviousyear.Accordingtothesource,NovoNordiskwillhavethelargestnewsalesin2023withsome3.4billiondollarsofincreasecomparedto2022.ReadmoreNote(s):Worldwide;asofDecember2022Source(s):Evaluate(EvaluatePharma);EvaluateVantage;CHAPTER

04R&D,patents,newproductsTotalglobalspendingonpharmaceuticalresearchanddevelopmentfrom2014to2028(inbillionU.S.dollars)TotalglobalpharmaceuticalR&Dspending2014-20283503002503022962892812722622492442111942001501005018517116115114502014201520162017201820192020202120222023*2024202520262027202827Description:In2022,researchanddevelopmentspendinginthepharmaceuticalindustrytotaledsome244billionU.S.dollarsglobally.Forcomparison,R&Dexpenditurestotaled137billiondollarsin2012.PharmaceuticalR&Dincludesallstepsfromtheinitialresearchofdiseaseprocesses,thecompoundtestingoverpre-clinical,andallclinicaltrialstages.Atacertainpointintheprocess-mostlyduringthepre-clinicalphase-agovernmentalauthorityisinvolvedtooverview,regulate,andultimately[...]

ReadmoreNote(s):Worldwide;asofAugust2023;*Allvaluesareprojectedfrom2023on.ReadmoreSource(s):EvaluateGlobaltop10pharmaceuticalcompaniesbasedonprojectedR&Dspendingin2026(inbillionU.S.dollars)GlobaltoppharmaceuticalcompaniesbasedonR&Dspending2026R&DspendinginbillionU.S.dollars024681012141416RocheJohnson&JohnsonMerck&Co12.211.4Pfizer10.5Novartis10Bristol-MyersSquibbAstraZenecaEliLilly98.68.17.9GlaxoSmithKlineAbbVie7.528Description:In2026,Swiss-basedRocheisprojectedtospend14billionU.S.dollarsonpharmaceuticalresearchanddevelopment.OthercompanieswithhighprojectedR&DexpendituresareMerck,Pfizer,andJohnson&Johnson.

ReadmoreNote(s):Worldwide;asofMay2021Source(s):EvaluateWorldwidetotalprescriptiondrugrevenueatriskfrompatentexpirationfrom2023to2028(inbillionU.S.dollars)Patentexpirationrisksfortotalworldwideprescriptiondrugrevenue2023-202812010080998060525146402002620232024202520262027202829Description:Thisstatisticdepictsthetotalprescriptiondrugrevenueworldwidethatisatriskduetopatentexpirationfrom2023to2028.In2023,theindustryisexpectedtohave51billionU.S.dollarsinprescriptiondrugsalesworldwideatriskduetopatentexpiration.Aftertheexpirationofpatentprotection,othercompaniesareallowedtomakecheapergenericsoftheoriginallybrandeddrug.ReadmoreNote(s):Worldwide;asofAugust2023Source(s):EvaluateShareofglobalprescriptiondrugrevenueatriskfrompatentexpirationfrom2023to2028Worldwideprescriptiondrugrevenue-marketriskfrompatentexpiration2023-20287%6%5%6.2%5.4%4.5%4.1%4%3%2%1%0%3.3%2.2%20242023202520262027202830Description:Thisstatisticdepictstheshareofworldwideprescriptiondrugrevenueatriskduetopatentexpirationsfrom2023to2028.In2023,some4.5percentoftheRxmarketwasatriskduetopatentexpirationsonpharmaceuticaldrugrevenues.

ReadmoreNote(s):Worldwide;asofAugust2023Source(s):EvaluateNumberofnewchemicalorbiologicalentitiesdevelopedbetween1998and2022,byregionoforiginPharmaceuticalindustry-numberofnewsubstances1998-20221998-20022003-20072008-20122013-20171591592014-20182015-20192016-20202017-20212018-2022*180160140120100801381251201007777747271686766

6564585560504848464141

413938363534402930261715152040EuropeUnitedStatesChinaNationalityofmothercompanyJapanOther31Description:Between2018and2022,Americancompaniesintroducedatotalof159newchemicalorbiologicalsubstances.Withinthesameperiod,EuropeandJapanproduced74and46newentities,respectively.

ReadmoreNote(s):WorldwideSource(s):EFPIATotalnumberofpharmaceuticalcompanieswithactiveR&Dpipelinesworldwidefrom2001to2023PharmacompaniesworldwidewithactiveR&Dpipelines2001-2023Numberofcompanies20232022202120202019201820172016201520142013201220115,5295,4165,0994,8164,3234,1344,0033,6873,2862,9842,7452,7052,38732Description:ThisstatisticshowsthetotalnumberofpharmaceuticalcompanieswithactiveR&Dpipelinesworldwidefrom2001to2023.In2001,therewere1,198pharmaceuticalcompanieswithactiveR&Dpipelines,andthisnumberincreaseduptoover5,500asofJanuary2023.ReadmoreNote(s):WorldwideSource(s):PharmaIntelligence(Citeline)TotalnumberofnoveldrugsapprovedbyCDERfrom2008to2022NumberofnoveldrugsapprovedannuallybyCDER2008-202270596050403020100535048464541393730272624222120082009201020112012201320142015201620172018201920202021202233Description:In2022,37noveldrugswereapprovedbytheCenterforDrugEvaluationandResearch(CDER).Thenumberofnewmedicinalproductsenteringthepharmaceuticalmarketeachyearvariesheavily:justover20noveldrugswereintroducedin2016,whileabout60newproductswereapprovedin2018.Therewere50approvalsfornoveldrugsin2021.

ReadmoreNote(s):UnitedStatesSource(s):FoodandDrugAdministration(CenterforDrugEvaluationandResearch(CDER))SelectedtoppharmaceuticalR&Dprojectsbasedonnetpresentvalue(NPV)asofJuly2023(inbillionU.S.dollars)ProjectedmostvaluableR&Dprojectsbasedonnetpresentvalue2023NPVinbillionU.S.dollars02468101214Sotatercept,Merck&CoDatopotamabderuxtecan,DaiichiSankyo/AstraZenecaCagriSema,NovoNordisk11.611.510.3Donanemab,EliLilly8.8KarXT,KarunaTherapeutics8.4mRNA-1647,Moderna7.134Description:ThisstatisticdisplaysthetoppharmaceuticalR&Dprojectsbasedonnetpresentvalue,asofJuly2023.Accordingtothesource,thetopR&DprojectwasMerck&Co.'spulmonaryarterialhypertensiontreatmentSotaterceptwithanetpresentvalueof11.6billionU.S.dollarsatthattime.ReadmoreNote(s):Worldwide;asofJuly2023Source(s):Evaluate(EvaluatePharma);EvaluateVantageCHAPTER

05OutlookProjectedglobalpharmaceuticalsalesfor2026,byregion(inbillionU.S.dollars)Worldpharmaceuticalsalesbyregionforecast2026SalesinbillionU.S.dollars295NorthAmericaEuropeanUnionSoutheast&EastAsiaChina774267189170LatinAmericaEuropenon-EU(incl.UK)8274JapanIndiansubcontinentCIS5240342919AfricaMiddleEastOceania36Description:TotalpharmaceuticalsalesnumbersinNorthAmericaareprojectedtoamounttosome774billionU.S.dollarsin2026,makingittheregionalsubmarketwiththehighestglobalpharmasalesbyfar.ReadmoreNote(s):Worldwide;asofSeptember2026Source(s):AstraZeneca;IQVIAGlobalspendingonmedicinesin2010,2022,andaforecastfor2027(inbillionU.S.dollars)Globalspendingonmedicines2010-20272,5002,0001,5001,9171,4821,00050008872010*2022**2027***37Description:Globalspendingonmedicinecontinuestogrow.In2022,approximately1.48trillionU.S.dollarshadbeenspentonmedicines,upfromjust887billionU.S.dollarsin2010.Thatnumberisexpectedtoincreasetoover1.9trillionbytheyear2027.Spendingonmedicineshasincreasedeverywhereglobally.However,theUnitedStatestakestheleadintotalmedicinesspendinggloballyandisexpectedtoremainthetopcountryformedicinesspendingthrough2027.

ReadmoreNote(s):Worldwide;asofNovember2021Source(s):IQVIAProjectedpharmaceuticalspendingCAGRworldwidebetween2023and2027,bymarketandproducttypeCAGRbyproducttypeinpharmaceuticalmarketsforecast2023-2027OriginalbrandsNon-originalbrandsUnbrandedgenericsOtherproduct9%8%7%6%5%4%3%2%1%0%8%7.5%6.5%6.5%6.5%6.5%6.5%6%5.5%5.5%4.5%4.5%4.5%2.5%2%0.5%GlobalDevelopedPharmergingLowerincome38Description:Thisstatisticshowstheprojectedcompoundannualgrowthrateinvariouspharmaceuticalmarketsfortheperiod2023-2027,bytypeofproduct.Inthetotalglobalpharmaceuticalmarket,originalbrandswillseeanestimated4.5percentofannualgrowthinpharmaspendingoverthegivenperiod.ReadmoreNote(s):Worldwide;asofNovember2022Source(s):IQVIA;Website(medicalbuyer.co.in)Projectedspendingonmedicineofselectedcountriesworldwidein2026(inbillionU.S.dollars)Countrycomparisoninspendingonmedicine2026SpendinginbillionU.S.dollarsMaximumestimate300Minimumestimate4000100200500600700800715UnitedStatesChina68522019096GermanyJapanFranceBrazilUnitedKingdomItaly76937352485147504645414137IndiaSpainCanadaRussiaSouthKoreaAustralia3632363231272521171539Description:In2026,theUnitedStatesisprojectedtospendbetween685and715billionU.S.dollarsonmedicine.EstimatesfortheUnitedStatesaremuchhigherthanthoseofothercountriesonthelist.Forthesameyear,Germany`sexpectedexpenditureestimateswerebetween76and96billionU.S.dollars.ReadmoreNote(s):Worldwide;asofNovember2021Source(s):IQVIAProjectedtop10pharmaceuticalproductsworldwidebasedonlifetimesalesasof2026(inbillionU.S.dollars)Topglobalbiopharmadrugsbylifetimesalesupto2026LifetimesalesfromlaunchinbillionU.S.dollars2021

2026*150050100200250300Humira(2003)Keytruda(2015)Lipitor(1997)Enbrel(1998)Remicade(1998)Revlimid(2005)Rituxan(1997)Advair(1988)Epogen(1988)Comirnaty(2020)40Description:Lipitor,whichwasintroducedbyPfizerbackin1997,isexpectedtobethedrugwiththethirdhighestlifetimesalesasof2026.Until2021,thecholesterol-loweringdrugaggregatedlifetimesalesofover163billionU.S.dollars,whichisexpectedtoincreaseforsome5.5billiondollarsuntil2026.ReadmoreNote(s):Worldwide;asofFebruary2022;*Projected.ReadmoreSource(s):Evaluate;FiercePharmaSalesforecastofleading10pharmaceuticalcompaniesworldwidein2028(inbillionU.S.dollars)Salesforecastoftoppharmaceuticalcompaniesworldwide2028SalesinbillionU.S.dollars300102040506070AbbVieRoche65.765Johnson&JohnsonMerck&Co62.359.7Pfizer57.155.254.5NovartisAstraZenecaSan